DaVita CEO Kent Thiry leaves his post

  • Push-out Score determined
  • After almost 20 years in the position
  • Accolades, praise and thanks for Thiry
  • Javier Rodriguez taking over
  • Thiry will remain as executive chairman at DaVita
  • Thiry said 90 words

(exechange) — Denver, Colorado, April 29, 2019 — Kent Thiry, chief executive of DaVita, leaves the position. As announced by DaVita Inc. in a news release and in a regulatory filing published on Monday, April 29, 2019, Kent J. Thiry leaves his post as chief executive officer at the provider of kidney care services after almost 20 years in the role, effective June 1, 2019.

It is the end of an era.

Among the 3,000 largest publicly held companies incorporated in the U.S. based on market capitalization, the average tenure of the CEOs who departed over the past 12 months was 7.7 years, according to data compiled by exechange. Only 10 percent of the CEOs who departed over the past 12 months left the position after more than 15 years.

Kent Thiry’s duties will be taken over by Javier J. Rodriguez, currently chief executive officer of the kidney care division of DaVita Inc.

“Multi-year succession planning process”

Kent Thiry’s imminent departure from the CEO post is explained as follows. DaVita said: “Today’s leadership announcement is part of a multi-year succession planning process that involved the consideration of both internal and external candidates.”

Thiry has been CEO of DaVita since 1999 and chairman or co-chairman of the board since that time.

Thiry will remain as executive chairman at DaVita

“Thiry will transition from his current role as chairman and CEO to executive chairman of DaVita’s board of directors,” DaVita said.

“Step down”

DaVita said that its board of directors “has unanimously elected Javier J. Rodriguez to succeed Kent Thiry as CEO of DaVita effective June 1, 2019.”

DaVita further said: “Mr. Rodriguez will replace Kent J. Thiry, who will step down as Chairman of the Board and Chief Executive Officer of the Company and DaVita Medical Group.”

Share price decline

The announcement follows a decline in DaVita Inc.’s share price of 34 percent since May 2015.

In the position of CEO since 1999

Kent J. Thiry has been the Chief Executive Officer of DaVita HealthCare Partners Inc. since October 18, 1999.

Kent J. Thiry has been the Company’s chairman of the Board since June 2015 and from October 1999 until November 2012, and the Company’s chief executive officer since October 1999.

In October 2014, Thiry also became chief executive officer of the Company’s integrated care business, DMG.

From November 2012 until June 2015, Thiry served as the Company’s co-chairman of the Board.

From June 1997 until he joined the Company in October 1999, Thiry was chairman of the board and chief executive officer of Vivra Holdings, Inc., which was formed to operate the non-dialysis business of Vivra Incorporated (“Vivra”) after Gambro AB acquired the dialysis services business of Vivra in June 1997.

From September 1992 to June 1997, Thiry was the president and chief executive officer of Vivra, a provider of renal dialysis services and other healthcare services.

From April 1992 to August 1992, Thiry was president and co-chief executive officer of Vivra, and from September 1991 to March 1992, he was president and chief operating officer of Vivra.

From 1983 to 1991, Thiry was associated with Bain & Company, first as a consultant, and then as vice president.

Thiry previously served on the board of Varian Medical Systems, Inc. from August 2005 to February 2009 and served as the non-executive chairman of Oxford Health Plans, Inc. until it was sold to UnitedHealth Group in July 2004.

As a member of management, Thiry provides significant healthcare industry experience and unique expertise regarding the Company’s business and operations as well as executive leadership and management experience.

Push-out Score determined

The Push-out Score™ determined by exechange gauges the pressure surrounding the management change on a scale of 0 to 10.

exechange reached out to DaVita and offered the company the opportunity to comment on the score.

Read the full story in the exechange report 18.2019 ($).